{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:01:08Z","timestamp":1780444868900,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL151735"],"award-info":[{"award-number":["R01HL151735"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03822-5","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T19:02:53Z","timestamp":1729537373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A low-dose pemetrexed-cisplatin combination regimen induces significant nephrotoxicity in mice"],"prefix":"10.1186","volume":"25","author":[{"given":"Samson A.","family":"Iwhiwhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul H.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah M.","family":"Afolabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jada D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia E.","family":"de la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebowale","family":"Adebiyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"10","key":"3822_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1023\/A:1008379101017","volume":"11","author":"AA Adjei","year":"2000","unstructured":"Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol. 2000;11(10):1335\u201341.","journal-title":"Ann Oncol"},{"issue":"4","key":"3822_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1345\/aph.1E329","volume":"39","author":"K Puto","year":"2005","unstructured":"Puto K, Garey JS. Pemetrexed therapy for malignant pleural mesothelioma. Ann Pharmacother. 2005;39(4):678\u201383.","journal-title":"Ann Pharmacother"},{"issue":"14","key":"3822_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3822_CR4","first-page":"1943","volume":"22","author":"YM Zhu","year":"2018","unstructured":"Zhu YM, Gan YL, Xu HY, Chen WH, Dai HP. Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):1943\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"3822_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1586\/14737140.5.2.231","volume":"5","author":"M Reck","year":"2005","unstructured":"Reck M, Gatzemeier U. Pemetrexed\u2013cisplatin combination in mesothelioma. Expert Rev Anticancer Ther. 2005;5(2):231\u20137.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"3822_CR6","first-page":"54","volume":"17","author":"JS Berns","year":"1997","unstructured":"Berns JS, Ford PA. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin Nephrol. 1997;17(1):54\u201366.","journal-title":"Semin Nephrol"},{"issue":"10","key":"3822_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrology: CJASN. 2012;7(10):1713\u201321.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"3822_CR8","doi-asserted-by":"crossref","unstructured":"Perazella MA, Rosner MH. Drug-Induced Acute kidney Injury. Clin J Am Soc Nephrol 2022, 17(8).","DOI":"10.2215\/CJN.11290821"},{"issue":"1","key":"3822_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","volume":"7","author":"JA Kellum","year":"2021","unstructured":"Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. 2021;7(1):52.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"3822_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994\u20131007.","journal-title":"Kidney Int"},{"issue":"1","key":"3822_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1214243","volume":"371","author":"LS Chawla","year":"2014","unstructured":"Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney Injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371(1):58\u201366.","journal-title":"N Engl J Med"},{"issue":"3","key":"3822_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000516647","volume":"146","author":"AS Levey","year":"2022","unstructured":"Levey AS. Defining AKD: the Spectrum of AKI, AKD, and CKD. Nephron. 2022;146(3):302\u20135.","journal-title":"Nephron"},{"issue":"5","key":"3822_CR13","doi-asserted-by":"publisher","first-page":"e203639","DOI":"10.1001\/jamanetworkopen.2020.3639","volume":"3","author":"KR McMahon","year":"2020","unstructured":"McMahon KR, Rassekh SR, Schultz KR, Blydt-Hansen T, Cuvelier GDE, Mammen C, Pinsk M, Carleton BC, Tsuyuki RT, Ross CJD, et al. Epidemiologic characteristics of Acute kidney Injury during Cisplatin infusions in Children treated for Cancer. JAMA Netw Open. 2020;3(5):e203639\u2013203639.","journal-title":"JAMA Netw Open"},{"key":"3822_CR14","doi-asserted-by":"publisher","first-page":"1173578","DOI":"10.3389\/fonc.2023.1173578","volume":"13","author":"F Trevisani","year":"2023","unstructured":"Trevisani F, Di Marco F, Quattrini G, Lepori N, Floris M, Valsecchi D, Giordano L, Dell\u2019Oca I, Cardellini S, Cinque A, et al. Acute kidney injury and acute kidney disease in high-dose cisplatin-treated head and neck cancer. Front Oncol. 2023;13:1173578.","journal-title":"Front Oncol"},{"key":"3822_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.lungcan.2020.05.022","volume":"146","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Boosman RJ, van de Bruinhorst H, Biesma B, van den Heuvel MM, Burger DM, Hilbrands LB, Ter Heine R, Derijks HJ. Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer. 2020;146:30\u20135.","journal-title":"Lung Cancer"},{"issue":"12","key":"3822_CR16","first-page":"4151","volume":"10","author":"V Chiruvella","year":"2020","unstructured":"Chiruvella V, Annamaraju P, Guddati AK. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am J Cancer Res. 2020;10(12):4151\u201364.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"3822_CR17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","volume":"15","author":"DW Dumoulin","year":"2020","unstructured":"Dumoulin DW, Visser S, Cornelissen R, van Gelder T, Vansteenkiste J, von der Thusen J, Aerts JGJV. Renal toxicity from Pemetrexed and Pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC. J Thorac Oncol. 2020;15(9):1472\u201383.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"3822_CR18","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","volume":"44","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Piet B, Derijks HJ, van den Heuvel MM, Ter Heine R. Mechanisms, Management and Prevention of Pemetrexed-related toxicity. Drug Saf. 2021;44(12):1271\u201381.","journal-title":"Drug Saf"},{"issue":"5","key":"3822_CR19","first-page":"769","volume":"2","author":"C Pi\u00e9rard-Franchimont","year":"2011","unstructured":"Pi\u00e9rard-Franchimont C, Quatresooz P, Reginster MA, Pi\u00e9rard GE. Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett. 2011;2(5):769\u201372.","journal-title":"Oncol Lett"},{"issue":"30","key":"3822_CR20","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1200\/JCO.2006.07.7016","volume":"24","author":"MA Socinski","year":"2006","unstructured":"Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol. 2006;24(30):4840\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3822_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44(5):372\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3822_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5414\/CN107921","volume":"82","author":"S Chauvet","year":"2014","unstructured":"Chauvet S, Courbebaisse M, Ronco P, Plaisier E. Pemetrexed-induced acute kidney injury leading to chronic kidney disease. Clin Nephrol. 2014;82(6):402\u20136.","journal-title":"Clin Nephrol"},{"issue":"5","key":"3822_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.cllc.2017.04.003","volume":"18","author":"CJ Langer","year":"2017","unstructured":"Langer CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, de Marinis F, Pujol J-L, San Antonio B, Chen J, Liu J, Oton AB, et al. Safety analyses of pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in patients with Advanced non-squamous NSCLC: retrospective analyses from 2 phase III studies. Clin Lung Cancer. 2017;18(5):489\u201396.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"3822_CR24","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.08070715","volume":"11","author":"S Latcha","year":"2016","unstructured":"Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after Cisplatin Treatment. Clin J Am Soc Nephrology: CJASN. 2016;11(7):1173\u20139.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"4","key":"3822_CR25","doi-asserted-by":"publisher","first-page":"1800884","DOI":"10.1183\/13993003.00884-2018","volume":"52","author":"S Visser","year":"2018","unstructured":"Visser S, Huisbrink J, Veer NE, van Toor Jermo J, Boxem AJMv W, NCv S, Bruno H, Aerts JGJV. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. 2018;52(4):1800884.","journal-title":"Eur Respir J"},{"issue":"6","key":"3822_CR26","first-page":"562","volume":"4","author":"K Muraki","year":"2012","unstructured":"Muraki K, Koyama R, Honma Y, Yagishita S, Shukuya T, Ohashi R, Takahashi F, Kido K, Iwakami S-i, Sasaki S, et al. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer. J Thorac Disease. 2012;4(6):562\u20138.","journal-title":"J Thorac Disease"},{"issue":"10","key":"3822_CR27","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.34067\/KID.0000000000000227","volume":"4","author":"J Liang","year":"2023","unstructured":"Liang J, Liu Y. Animal models of kidney disease: challenges and perspectives. Kidney360. 2023;4(10):1479\u201393.","journal-title":"Kidney360"},{"key":"3822_CR28","doi-asserted-by":"crossref","unstructured":"Szturz P, Vermorken JB. High-dose three-Weekly or Low-Dose Weekly Cisplatin during Radiation, what to prefer? Critical issues in Head and Neck Oncology: 2021\/\/ 2021; Cham. Springer International Publishing; 2021. pp. 139\u201353.","DOI":"10.1007\/978-3-030-63234-2_10"},{"issue":"3","key":"3822_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jjco\/hye019","volume":"31","author":"Y Ohe","year":"2001","unstructured":"Ohe Y, Niho S, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Kunitoh H, Saijo N, Nishiwaki Y. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn J Clin Oncol. 2001;31(3):100\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"3822_CR30","first-page":"924","volume":"32","author":"J Ma\u0142yszko","year":"2016","unstructured":"Ma\u0142yszko J, Koz\u0142owska K, Koz\u0142owski L, Ma\u0142yszko J. Nephrotoxicity of anticancer treatment. Nephrol Dialysis Transplantation. 2016;32(6):924\u201336.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"6","key":"3822_CR31","doi-asserted-by":"publisher","first-page":"F560","DOI":"10.1152\/ajprenal.00512.2015","volume":"310","author":"CN Sharp","year":"2016","unstructured":"Sharp CN, Doll MA, Dupre TV, Shah PP, Subathra M, Siow D, Arteel GE, Megyesi J, Beverly LJ, Siskind LJ. Repeated administration of low-dose cisplatin in mice induces fibrosis. Am J Physiol Ren Physiol. 2016;310(6):F560\u2013568.","journal-title":"Am J Physiol Ren Physiol"},{"key":"3822_CR32","doi-asserted-by":"crossref","unstructured":"Per\u0161e M, Ve\u010deri\u0107-Haler \u017d. Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges. BioMed research international 2018, 2018:1462802.","DOI":"10.1155\/2018\/1462802"},{"issue":"10","key":"3822_CR33","doi-asserted-by":"publisher","first-page":"F972","DOI":"10.1152\/ajprenal.00552.2015","volume":"310","author":"NI Skrypnyk","year":"2016","unstructured":"Skrypnyk NI, Siskind LJ, Faubel S, de Caestecker MP. Bridging translation for acute kidney injury with better preclinical modeling of human disease. Am J Physiol Ren Physiol. 2016;310(10):F972\u2013984.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1","key":"3822_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/jcmm.13926","volume":"23","author":"H Soni","year":"2019","unstructured":"Soni H, Matthews AT, Pallikkuth S, Gangaraju R, Adebiyi A. \u03b3-secretase inhibitor DAPT mitigates cisplatin-induced acute kidney injury by suppressing Notch1 signaling. J Cell Mol Med. 2019;23(1):260\u201370.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3822_CR35","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/0886022X.2018.1456938","volume":"40","author":"H Soni","year":"2018","unstructured":"Soni H, Kaminski D, Gangaraju R, Adebiyi A. Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding. Ren Fail. 2018;40(1):314\u201322.","journal-title":"Ren Fail"},{"issue":"5","key":"3822_CR36","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1073\/pnas.1011379108","volume":"108","author":"S Dhar","year":"2011","unstructured":"Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011;108(5):1850\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"3822_CR37","doi-asserted-by":"publisher","first-page":"11294","DOI":"10.1073\/pnas.1203129109","volume":"109","author":"P Sengupta","year":"2012","unstructured":"Sengupta P, Basu S, Soni S, Pandey A, Roy B, Oh MS, Chin KT, Paraskar AS, Sarangi S, Connor Y, et al. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A. 2012;109(28):11294\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3822_CR38","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.3109\/10717544.2015.1033794","volume":"23","author":"N Lu","year":"2016","unstructured":"Lu N, Li R, Liu Q, Hu B, Xu X, Ji C, Han X, Wang P, Liu B. Antitumor and antimetastatic effects of pemetrexed-loaded targeted nanoparticles in B16 bearing mice. Drug Delivery. 2016;23(7):2566\u201374.","journal-title":"Drug Delivery"},{"issue":"11","key":"3822_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/ki.2011.31","volume":"79","author":"D Schock-Kusch","year":"2011","unstructured":"Schock-Kusch D, Xie Q, Shulhevich Y, Hesser J, Stsepankou D, Sadick M, Koenig S, Hoecklin F, Pill J, Gretz N. Transcutaneous assessment of renal function in conscious rats with a device for measuring FITC-sinistrin disappearance curves. Kidney Int. 2011;79(11):1254\u20138.","journal-title":"Kidney Int"},{"issue":"5","key":"3822_CR40","doi-asserted-by":"publisher","first-page":"106583","DOI":"10.1016\/j.ijantimicag.2022.106583","volume":"59","author":"GM Pais","year":"2022","unstructured":"Pais GM, Chang J, Liu J, Scheetz MH. A translational rat model to assess glomerular function changes with Vancomycin. Int J Antimicrob Agents. 2022;59(5):106583.","journal-title":"Int J Antimicrob Agents"},{"key":"3822_CR41","doi-asserted-by":"crossref","unstructured":"Fanous MS, Afolabi JM, Michael OS, Falayi OO, Iwhiwhu SA, Adebiyi A. Transdermal measurement of glomerular filtration rate in mechanically ventilated piglets. J Vis Exp 2022(187).","DOI":"10.3791\/64413-v"},{"issue":"6","key":"3822_CR42","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/76299","volume":"6","author":"IM Shih","year":"2000","unstructured":"Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, Vogelstein B. Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. Nat Med. 2000;6(6):711\u20134.","journal-title":"Nat Med"},{"issue":"4","key":"3822_CR43","doi-asserted-by":"publisher","first-page":"zqad022","DOI":"10.1093\/function\/zqad022","volume":"4","author":"JM Afolabi","year":"2023","unstructured":"Afolabi JM, Kanthakumar P, Williams JD, Kumar R, Soni H, Adebiyi A. Post-injury Inhibition of Endothelin-1 Dependent Renal Vasoregulation mitigates Rhabdomyolysis-Induced Acute kidney Injury. Function (Oxf). 2023;4(4):zqad022.","journal-title":"Function (Oxf)"},{"issue":"1","key":"3822_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/13510002.2019.1596429","volume":"24","author":"H Soni","year":"2019","unstructured":"Soni H, Yakimkova T, Matthews AT, Amartey PK, Read RW, Buddington RK, Adebiyi A. Early onset of renal oxidative stress in small for gestational age newborn pigs. Redox Rep. 2019;24(1):10\u20136.","journal-title":"Redox Rep"},{"issue":"4 Suppl","key":"3822_CR45","doi-asserted-by":"publisher","first-page":"s14","DOI":"10.1177\/0192623312438736","volume":"40","author":"KS Frazier","year":"2012","unstructured":"Frazier KS, Seely JC, Hard GC, Betton G, Burnett R, Nakatsuji S, Nishikawa A, Durchfeld-Meyer B, Bube A. Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol Pathol. 2012;40(4 Suppl):s14\u201386.","journal-title":"Toxicol Pathol"},{"issue":"23","key":"3822_CR46","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"R Bayat Mokhtari","year":"2017","unstructured":"Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022\u201343.","journal-title":"Oncotarget"},{"key":"3822_CR47","doi-asserted-by":"crossref","unstructured":"Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009, 20(11).","DOI":"10.1681\/ASN.2009020171"},{"issue":"5","key":"3822_CR48","first-page":"370","volume":"18","author":"M Nematbakhsh","year":"2013","unstructured":"Nematbakhsh M, Ashrafi F, Nasri H, Talebi A, Pezeshki Z, Eshraghi F, Haghighi M. A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats. J Res Med Sci. 2013;18(5):370\u20133.","journal-title":"J Res Med Sci"},{"key":"3822_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1146\/annurev-physiol-020518-114605","volume":"81","author":"WR Zhang","year":"2019","unstructured":"Zhang WR, Parikh CR. Biomarkers of Acute and chronic kidney disease. Annu Rev Physiol. 2019;81:309\u201333.","journal-title":"Annu Rev Physiol"},{"key":"3822_CR50","doi-asserted-by":"crossref","unstructured":"Hamlin DM, Schultze AE, Coyne MJ, McCrann DJI, Mack R, Drake C, Murphy RE, Cross J, Strong-Townsend M, Yerramilli M et al. Evaluation of Renal Biomarkers, Including Symmetric Dimethylarginine, following Gentamicin-Induced Proximal Tubular Injury in the Rat. Kidney360 2022, 3(2):341\u2013356.","DOI":"10.34067\/KID.0006542020"},{"issue":"3","key":"3822_CR51","doi-asserted-by":"publisher","first-page":"F626","DOI":"10.1152\/ajprenal.00004.2011","volume":"300","author":"S Bolisetty","year":"2011","unstructured":"Bolisetty S, Agarwal A. Urine albumin as a biomarker in acute kidney injury. Am J Physiol Ren Physiol. 2011;300(3):F626\u2013627.","journal-title":"Am J Physiol Ren Physiol"},{"issue":"3","key":"3822_CR52","doi-asserted-by":"publisher","first-page":"F628","DOI":"10.1152\/ajprenal.00654.2010","volume":"300","author":"LB Ware","year":"2011","unstructured":"Ware LB, Johnson AC, Zager RA. Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury. Am J Physiol Ren Physiol. 2011;300(3):F628\u2013638.","journal-title":"Am J Physiol Ren Physiol"},{"key":"3822_CR53","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/00365510802150158","volume":"241","author":"P Devarajan","year":"2008","unstructured":"Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of kidney disease. Scand J Clin Lab Invest Suppl. 2008;241:89\u201394.","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"3822_CR54","doi-asserted-by":"publisher","first-page":"102754","DOI":"10.1016\/j.redox.2023.102754","volume":"63","author":"H Jiang","year":"2023","unstructured":"Jiang H, Zuo J, Li B, Chen R, Luo K, Xiang X, Lu S, Huang C, Liu L, Tang J, et al. Drug-induced oxidative stress in cancer treatments: Angel or Devil? Redox Biol. 2023;63:102754.","journal-title":"Redox Biol"},{"issue":"3","key":"3822_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/ars.2016.6665","volume":"25","author":"BB Ratliff","year":"2016","unstructured":"Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant mechanisms in Renal Injury and Disease. Antioxid Redox Signal. 2016;25(3):119\u201346.","journal-title":"Antioxid Redox Signal"},{"key":"3822_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1146\/annurev-biochem-061516-045037","volume":"86","author":"H Sies","year":"2017","unstructured":"Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem. 2017;86:715\u201348.","journal-title":"Annu Rev Biochem"},{"key":"3822_CR57","doi-asserted-by":"crossref","unstructured":"Gyur\u00e1szov\u00e1 M, Gureck\u00e1 R, B\u00e1b\u00ed\u010dkov\u00e1 J, T\u00f3thov\u00e1 \u013d. Oxidative Stress in the Pathophysiology of Kidney Disease: Implications for Noninvasive Monitoring and Identification of Biomarkers. Oxid Med Cell Longev 2020, 2020:5478708.","DOI":"10.1155\/2020\/5478708"},{"issue":"12","key":"3822_CR58","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1089\/ars.2016.6804","volume":"25","author":"Y Gorin","year":"2016","unstructured":"Gorin Y. The kidney: an Organ in the Front line of oxidative stress-Associated pathologies. Antioxid Redox Signal. 2016;25(12):639\u201341.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"3822_CR59","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s42255-022-00591-z","volume":"4","author":"MP Murphy","year":"2022","unstructured":"Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metabolism. 2022;4(6):651\u201362.","journal-title":"Nat Metabolism"},{"issue":"4","key":"3822_CR60","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0891-5849(99)00264-6","volume":"28","author":"LJ Roberts","year":"2000","unstructured":"Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med. 2000;28(4):505\u201313.","journal-title":"Free Radic Biol Med"},{"issue":"2\u20133","key":"3822_CR61","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0014-5793(97)00469-9","volume":"411","author":"B Halliwell","year":"1997","unstructured":"Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo? FEBS Lett. 1997;411(2\u20133):157\u201360.","journal-title":"FEBS Lett"},{"issue":"10","key":"3822_CR62","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.humimm.2013.06.009","volume":"74","author":"H Ahsan","year":"2013","unstructured":"Ahsan H. 3-Nitrotyrosine: a biomarker of nitrogen free radical species modified proteins in systemic autoimmunogenic conditions. Hum Immunol. 2013;74(10):1392\u20139.","journal-title":"Hum Immunol"},{"issue":"14","key":"3822_CR63","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1111\/jcmm.17799","volume":"27","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhang C, Jin S, Li J, Dai J, Zhang Z, Guo R. Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC. J Cell Mol Med. 2023;27(14):2032\u201344.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"3822_CR64","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00204-006-0173-2","volume":"81","author":"NAG Santos","year":"2007","unstructured":"Santos NAG, Cat\u00e3o CS, Martins NM, Curti C, Bianchi MLP, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007;81(7):495\u2013504.","journal-title":"Arch Toxicol"},{"issue":"1","key":"3822_CR65","doi-asserted-by":"publisher","first-page":"e0279928","DOI":"10.1371\/journal.pone.0279928","volume":"18","author":"W Zhu","year":"2023","unstructured":"Zhu W, Barreto EF, Li J, Lee HK, Kashani K. Drug-drug interaction and acute kidney injury development: a correlation-based network analysis. PLoS ONE. 2023;18(1):e0279928.","journal-title":"PLoS ONE"},{"issue":"12","key":"3822_CR66","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2215\/CJN.00150118","volume":"13","author":"MA Perazella","year":"2018","unstructured":"Perazella MA. Pharmacology behind Common Drug Nephrotoxicities. Clin J Am Soc Nephrol. 2018;13(12):1897\u2013908.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"3822_CR67","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S0272-6386(86)80111-1","volume":"8","author":"R Safirstein","year":"1986","unstructured":"Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. Am J Kidney Diseases: Official J Natl Kidney Foundation. 1986;8(5):356\u201367.","journal-title":"Am J Kidney Diseases: Official J Natl Kidney Foundation"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03822-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03822-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T20:03:05Z","timestamp":1729540985000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03822-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3822"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03822-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Animal Care and Use Committee of the University of Tennessee Health Science Center (UTHSC) approved the study protocol (IACUC # 19\u2013027.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"370"}}